ULK1 Modulation Shows Promise in Cancer Therapy with DCC-3116 in Clinical Evaluation
DCC-3116, the first clinical agent targeting ULK1, shows on-target engagement and acceptable tolerability.
Asset / Drug
Drug and asset intelligence for DCC-3116 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.